{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:11:00Z","timestamp":1769019060687,"version":"3.49.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The introduction of new drugs with less severe toxicity profiles than those of conventional antimyeloma agents allowed the evaluation of continuous therapy compared with fixed duration therapy. In transplant-eligible patients, consolidation therapy with bortezomib or bortezomib-based regimens showed significant progression-free survival (PFS) benefit in cytogenetic standard-risk patients and to a lesser extent, high-risk patients. Continuous therapy with lenalidomide maintenance treatment after autologous stem cell transplantation resulted in a significant survival gain. In transplant noneligible patients, continuous lenalidomide-dexamethasone therapy improved survival over fixed duration melphalan-prednisone-thalidomide. The concept of prolonged treatment in elderly patients is supported by some other studies, but most of them revealed a gain in PFS only. Young patients with unfavorable prognosis show a greater willingness to accept long-term treatment, whereas the readiness to undergo such treatments and the benefits therefrom decline with increasing age and decreasing fitness, rendering fixed duration therapy a suitable option in elderly frail patients.<\/jats:p>","DOI":"10.1182\/asheducation-2017.1.212","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T18:13:11Z","timestamp":1555438391000},"page":"212-222","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["Fixed duration vs continuous therapy in multiple myeloma"],"prefix":"10.1182","volume":"2017","author":[{"given":"Heinz","family":"Ludwig","sequence":"first","affiliation":[{"name":"Wilhelminen Cancer Research Institute, Department of Medicine I, Center for Medical Oncology, Hematology and Outpatient Department and Palliative Care, Wilhelminenspital, Vienna, Austria; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklas","family":"Zojer","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Center for Medical Oncology, Hematology and Outpatient Department and Palliative Care, Wilhelminenspital, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"5","key":"2019111703351478500_B1","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"2019111703351478500_B2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4155\/ppa.14.18","article-title":"Recent advances in antimultiple myeloma drug development","volume":"3","author":"Wang","year":"2014","journal-title":"Pharm Pat Anal"},{"issue":"1","key":"2019111703351478500_B3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/bjc.1988.17","article-title":"A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients","volume":"57","author":"Belch","year":"1988","journal-title":"Br J Cancer"},{"issue":"9","key":"2019111703351478500_B4","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood.V99.9.3163","article-title":"Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients","volume":"99","author":"Berenson","year":"2002","journal-title":"Blood"},{"issue":"2","key":"2019111703351478500_B5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2141.2006.06405.x","article-title":"A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7","volume":"136","author":"Shustik","year":"2007","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111703351478500_B6","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1365-2141.2001.02857.x","article-title":"Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients","volume":"113","author":"Myeloma Trialists\u2019 Collaborative Group","year":"2001","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111703351478500_B7","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1023\/A:1026548226770","article-title":"Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients","volume":"11","author":"Fritz","year":"2000","journal-title":"Ann Oncol"},{"issue":"4","key":"2019111703351478500_B8","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1200\/JCO.1997.15.4.1672","article-title":"Patient preferences for interferon alfa in multiple myeloma","volume":"15","author":"Ludwig","year":"1997","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111703351478500_B9","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1200\/JCO.2009.23.7172","article-title":"Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma","volume":"28","author":"Ladetto","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111703351478500_B10","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/leu.2014.219","article-title":"Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics\u2019 impact on survival","volume":"29","author":"Ferrero","year":"2015","journal-title":"Leukemia"},{"issue":"23","key":"2019111703351478500_B11","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1182\/blood-2012-11-464503","article-title":"Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial","volume":"121","author":"Mellqvist","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2019111703351478500_B12","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1038\/leu.2017.83","article-title":"Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma","volume":"31","author":"Einsele","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"2019111703351478500_B13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/bjh.14637","article-title":"Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study","volume":"178","author":"Sezer","year":"2017","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111703351478500_B14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2012-02-408898","article-title":"Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma","volume":"120","author":"Cavo","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2019111703351478500_B15","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1038\/leu.2013.101","article-title":"Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma","volume":"27","author":"Leleu","year":"2013","journal-title":"Leukemia"},{"issue":"22","key":"2019111703351478500_B16","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood.V128.22.242.242","article-title":"Consolidation followed by maintenance therapy versus maintenance alone in newly diagnosed, transplant eligible patients with multiple myeloma (MM): a randomized phase 3 study of the European Myeloma Network (EMN02\/HO95 MM Trial) [abstract]","volume":"128","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"2019111703351478500_B17","first-page":"LBA-1","article-title":"Comparison of autologous hematopoietic cell transplant (autoHCT), bortezomib, lenalidomide (Len) and dexamethasone (RVD) consolidation with Len maintenance (ACM), tandem Autohct with Len maintenance (TAM) and Autohct with Len maintenance (AM) for up-front treatment of patients with multiple myeloma (MM): primary results from the randomized phase III trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 \u2013 StaMINA Trial) [abstract]","author":"Stadtmauer","year":"2016"},{"issue":"22","key":"2019111703351478500_B18","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/blood.V128.22.244.244","article-title":"Response adapted induction treatment improves outcomes for myeloma patients; results of the phase III Myeloma XI Study [abstract]","volume":"128","author":"Jackson","year":"2016","journal-title":"Blood"},{"issue":"13","key":"2019111703351478500_B19","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1182\/blood-2011-11-374249","article-title":"IMWG consensus on maintenance therapy in multiple myeloma","volume":"119","author":"Ludwig","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111703351478500_B20","first-page":"djv342","article-title":"Maintenance therapy with immunomodulatory drugs in multiple myeloma: a meta-analysis and systematic review","volume":"108","author":"Wang","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"21","key":"2019111703351478500_B21","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-12-3211","article-title":"Long-term follow-up of MRC Myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment","volume":"19","author":"Morgan","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2019111703351478500_B22","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","article-title":"A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma","volume":"115","author":"Lokhorst","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2019111703351478500_B23","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoietic-cell transplantation for multiple myeloma","volume":"354","author":"Barlogie","year":"2006","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111703351478500_B24","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111703351478500_B25","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111703351478500_B26","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"key":"2019111703351478500_B27","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis [published online ahead of print 25 July 2017]","volume-title":"J Clin Oncol","author":"McCarthy"},{"issue":"22","key":"2019111703351478500_B28","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1182\/blood.V128.22.1143.1143","article-title":"Lenalidomide is a highly effective maintenance therapy in myeloma patients of all ages; results of the phase III Myeloma XI Study [abstract]","volume":"128","author":"Jackson","year":"2016","journal-title":"Blood"},{"issue":"24","key":"2019111703351478500_B29","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111703351478500_B30","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1038\/leu.2017.35","article-title":"Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA\/GEM trial","volume":"31","author":"Rosi\u00f1ol","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"2019111703351478500_B31","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/leu.2013.335","article-title":"Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients","volume":"28","author":"Nooka","year":"2014","journal-title":"Leukemia"},{"issue":"22","key":"2019111703351478500_B32","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1182\/blood.V128.22.675.675","article-title":"Final Results of a phase 2 trial of extended treatment (tx) with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (KRd) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM) [abstract]","volume":"128","author":"Zimmerman","year":"2016","journal-title":"Blood"},{"issue":"16","key":"2019111703351478500_B33","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol"},{"issue":"21","key":"2019111703351478500_B34","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2009-11-255620","article-title":"Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance","volume":"115","author":"Nair","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2019111703351478500_B35","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival","volume":"32","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111703351478500_B36","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2012-05-427815","article-title":"Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial","volume":"120","author":"Mateos","year":"2012","journal-title":"Blood"},{"issue":"19","key":"2019111703351478500_B37","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111703351478500_B38","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"issue":"13","key":"2019111703351478500_B39","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","article-title":"Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma","volume":"128","author":"Weinhold","year":"2016","journal-title":"Blood"},{"key":"2019111703351478500_B40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.critrevonc.2017.01.011","article-title":"Immunotherapy for the treatment of multiple myeloma","volume":"111","author":"Jung","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"24","key":"2019111703351478500_B41","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 Trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/212\/1249799\/hem00029.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/212\/1249799\/hem00029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T03:35:24Z","timestamp":1573961724000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2017\/1\/212\/21058\/Fixed-duration-vs-continuous-therapy-in-multiple"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2017.1.212","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]}}}